This indicates that hs-CRP primarily signals the inflammatory threshold triggering subclinical cardiac injury, while subsequent injury progression, though linked to initial or ongoing inflammation, follows a new trajectory influenced by multiple factors including primary inflammation (cancer, or ANT-induced), anti-HER2 agents, and potential intrinsic cardiac factors. This evidence concerns the gene ERBB2 and cancer.